Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Net Cash Flow: 2016-2024

Historic Net Cash Flow for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to $12.6 million.

  • Mereo BioPharma Group's Net Cash Flow rose 13.61% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.5 million, marking a year-over-year decrease of 312.50%. This contributed to the annual value of $12.6 million for FY2024, which is 192.90% up from last year.
  • As of FY2024, Mereo BioPharma Group's Net Cash Flow stood at $12.6 million, which was up 192.90% from -$13.6 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Net Cash Flow ranged from a high of $97.0 million in FY2021 and a low of -$46.6 million during FY2022.
  • For the 3-year period, Mereo BioPharma Group's Net Cash Flow averaged around -$15.9 million, with its median value being -$13.6 million (2023).
  • As far as peak fluctuations go, Mereo BioPharma Group's Net Cash Flow skyrocketed by 857.70% in 2021, and later plummeted by 148.05% in 2022.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Net Cash Flow stood at $10.1 million in 2020, then skyrocketed by 857.70% to $97.0 million in 2021, then crashed by 148.05% to -$46.6 million in 2022, then soared by 70.88% to -$13.6 million in 2023, then surged by 192.90% to $12.6 million in 2024.